Isolated limb perfusion with cisplatin and doxorubicin for locally advanced soft tissue sarcoma of an extremity

被引:12
|
作者
Eroglu, A [1 ]
Kocaoglu, H [1 ]
Demirci, S [1 ]
Akgül, H [1 ]
机构
[1] Ankara Univ, Sch Med, Dept Surg Oncol, TR-06100 Ankara, Turkey
来源
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY | 2000年 / 26卷 / 03期
关键词
soft tissue sarcoma; survival; isolated perfusion; cisplatin; doxorubicin;
D O I
10.1053/ejso.1999.0779
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: To identify independent adverse clinico-pathological factors for disease-free and overall survival in patients undergoing isolated limb perfusion (ILP) with cisplatin and doxorubicin for locally advanced soft tissue sarcoma (STS) of an extremity. Methods: A retrospective analysis was carried out, using a univariate method and a multivariate analysis, to look at the patient, tumour and treatment associated with prognostic factors in 37 patients with locally advanced STSs of the limbs who underwent ILP with cisplatin and doxorubicin. Patient's age, gender, presenting status, tumour location, tumour grade, tumour stage according to TNM classification, tumour size and radiotherapy (RT) were analysed. Survival curves were calculated according to the Kaplan-Meier method. A Cox proportional hazard model was used to indicate which factors related to overall survival and the recurrence-free interval after ILP. Results: No major systemic toxicity was seen. Regional toxicity was limited. Limb salvage was achieved in 94.6% of the patients. The estimated 5-year overall and disease-free survival rates were 62% and 54%, respectively. It was found that tumour stage, tumour grade, presenting status, RT and tumour size were associated with cumulative overall survival when the Kaplan-Meier method was applied (P<0.05). By Cox proportional hazards model, only tumour grade (P=0.0254) was found to have significant influence on overall survival; however, tumour stage (P=0.0157) and RT (P=0.0014) were related to disease-free survival. Conclusions: ILP and delayed excision followed by RT achieves good limb salvage rates and may improve survival.
引用
收藏
页码:213 / 221
页数:9
相关论文
共 50 条
  • [31] TNF Dose Reduction and Shortening of Duration of Isolated Limb Perfusion for Locally Advanced Soft Tissue Sarcoma of the Extremities Is Safe and Effective in Terms of Long-Term Patient Outcome
    Hoven-Gondrie, Miriam L.
    Bastiaannet, Esther
    van Ginkel, Robert J.
    Suurmeijer, Albert J. H.
    Hoekstra, Harald J.
    JOURNAL OF SURGICAL ONCOLOGY, 2011, 103 (07) : 648 - 655
  • [32] Neoadjuvant isolated limb perfusion in newly diagnosed untreated patients with locally advanced soft tissue sarcomas of the extremities: the Gustave Roussy experience
    T. Assi
    A. Cavalcanti
    A. Le Cesne
    M. Faron
    J. F. Honart
    A. Hadiji
    O. Camuzard
    T. Ibrahim
    C. LePéchoux
    O. Mir
    S. Dumont
    P. Terrier
    J. Adam
    C. Honoré
    Clinical and Translational Oncology, 2019, 21 : 1135 - 1141
  • [33] Neoadjuvant isolated limb perfusion in newly diagnosed untreated patients with locally advanced soft tissue sarcomas of the extremities: the Gustave Roussy experience
    Assi, T.
    Cavalcanti, A.
    Le Cesne, A.
    Faron, M.
    Honart, J. F.
    Hadiji, A.
    Camuzard, O.
    Ibrahim, T.
    LePechoux, C.
    Mir, O.
    Dumont, S.
    Terrier, P.
    Adam, J.
    Honore, C.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (09) : 1135 - 1141
  • [34] Soft tissue sarcoma of the extremity
    Cooper, TM
    Collins, D
    Sheehan, M
    OConnor, TP
    ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 1996, 78 (05) : 453 - 456
  • [35] Health-related quality of life after isolated limb perfusion compared to extended resection, or amputation for locally advanced extremity sarcoma: Is a limb salvage strategy worth the effort?
    Reijers, Sophie J. M.
    Husson, Olga
    Soomers, Vicky L. M. N.
    Been, Lukas B.
    Bonenkamp, Johannes J.
    van de Sande, Michiel A. J.
    Verhoef, Cornelis
    van der Graaf, Winette T. A.
    van Houdt, Winan J.
    EJSO, 2022, 48 (03): : 500 - 507
  • [36] Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma
    H. G. Smith
    J. Cartwright
    M. J. Wilkinson
    D. C. Strauss
    J. M. Thomas
    A. J. Hayes
    Annals of Surgical Oncology, 2015, 22 : 356 - 361
  • [37] Prognostic relevance of 18F-FDG PET uptake in patients with locally advanced, extremity soft tissue sarcomas undergoing neoadjuvant isolated limb perfusion with TNF-α and melphalan
    Dimosthenis Andreou
    Henrike Boldt
    Daniel Pink
    Björn Jobke
    Mathias Werner
    Markus Schuler
    Peter Reichardt
    Per-Ulf Tunn
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 1076 - 1083
  • [38] Isolated limb perfusion and infusion in the treatment of melanoma and soft tissue sarcoma in the era of modern systemic therapies
    Song, Yun
    Bruce, Adrienne N.
    Fraker, Douglas L.
    Karakousis, Giorgos C.
    JOURNAL OF SURGICAL ONCOLOGY, 2019, 120 (03) : 540 - 549
  • [39] Isolated limb perfusion with rhTNF-α and melphalan for locally recurrent childhood synovial sarcoma of the limb
    Hohenberger, P
    Tunn, PUF
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (11) : 905 - 909
  • [40] HYPERTHERMIC ANTIBLASTIC PERFUSION FOR THE TREATMENT OF SOFT-TISSUE LIMB SARCOMA
    DIFILIPPO, F
    GIANNARELLI, D
    BOTTI, C
    CARLINI, S
    CAVALIERE, F
    GARINEI, R
    SCHIRATTI, M
    CASALDI, V
    TEDESCO, M
    CAVALIERE, R
    ANNALS OF ONCOLOGY, 1992, 3 : S71 - S74